Here at Phil’s Stock World, we try to offer the best of all possible worlds. Phil has the rounded techniques of using options, covered calls, shorting and overall market direction to a prime. David Ristau gives us one up and one down pick of the day for 2-3% gains (he has been on a roll), and Optrader satisfies the swing trades. And then there is me, Pharmboy. I try to investigate the science behind the scenes to give the best possible chances to our readers on entering stocks we think will be profitable trades.
Take Ariad (ARIA), which I wrote about in August 2009. We had several different approaches, but the favorite was buying the stock at $1.30, selling and equal amount of the February 2010 $2.50 puts and calls which if the stock was $2.50 or above on OPEX, one would have made 68% ( in other words, 100 shares of stock with 1 call and 1 put sold would have gained 68% of the original $1.90). Where did ARIA finish up on the February OPEX…. $2.54. Lucky, somewhat on the OPEX play, but ARIA has been one of the core biotech holdings at PSW, along with DCTH (we jumped on this stock at about $5), CRIS (in at $1.21), KERX, and QCOR. Now, not all are perfect, as we have had a few that have gone south on us, most notably GILD. (Actually, Optrader correctly picked the direction on them a week back and I should have paid more attention to his 5d MA strategy.)
PSW has a great group of traders and investors that are willing to offer advice and point to better option and stock plays for all to benefit. As Phil notes, the more eyes on the charts and the market gives us the distinct advantage to play the game with them, not against!
Next, on to a few picks that could have us very happy in the next 6-18 months….
The picks I am outlining today are a bit more risky than past posts, but I believe they have the potential to make it to the game. They may not be a market leader, or the next Genentech, but I believe they have the right ‘products’ in place if management acts…
Reuters has had some questionable problems with its data in the past like their decision to "tweak" their polling methodology when Trump took his first inexplicable lead over Hillary back in July (see our post entitled "Hillary Lead Over Trump Surges After Reuters "Tweaks" Poll"). Well the latest Reuters/Ipsos poll as of 8/25/16 suggests that Hillary's "lead" over Trump seems to be vanishing...may be getting close t...
Boyar Value Group letter for the second quarter ended June 30, 2016.
Boyar Value Group – Some Thoughts About The Market
The two-day decline in the U.S. stock market subsequent to Great Britain’s decision to exit the European Union saw the Dow Jones Industrial Average plummet by 871 points. However, it climbed 809 points in the next four days and continued its ascent thereafter.
This leaves investors in a familiar quandary: Questioning what catalysts could spur the market to new highs. In our last quarterly letter, we mentioned the Federal Reserve had forecasted four interest rate hikes for 2016. We opined that in all likelihood there would be only one additional rate hike, and that might not come until after the presidential election. The fragile global economic outlook coupled with anemic dome...
Traders, bloggers, media talking heads, and pundits of all stripes went into a feverish sweat as they anticipated the comments of Federal Reserve Chairman Janet Yellen at the annual economic summit held in Jackson Hole, Wyoming. When Yellen, arguably the most dovish Fed Chairman in history, uttered, “I believe the case for an increase in the federal funds rate has strengthened in recent months,” an endless stream of commentators used this opportunity to spout out a never-ending stream of predictions describing the looming consequences of such a potential rate increase.
As I’ve stated before, the Fed receives both too much blame and too much credit for...
Only two of the eight equity indexes on our global watch list posted week-over-week gains in our latest update, same as last week. The two Eurozone indexes, France's CAC and Germany's DAXK, were the two who finished in the green, a shift from the Asian advance the previous week, when the Shanghai and Hang Seng were the sole gainers. In fact, the Shanghai Composite did a complete flip from its 1.88% gain the previous week to its -1.22% finish on Friday. The average of the eight improved fractionally from -0.56% the previous week to -0.39% for the latest.
A Closer Look at the Last Four Weeks
The tables below provide a concise overview of performance comparisons over the past four weeks for these eight major indexes. We'...
Before-tax corporate earnings fell 4.9 percent in the second quarter from a year earlier, the fifth consecutive decline and the worst streak since the end of the recession in mid-2009, Commerce Department figures showed on Friday.
Reminder: Pharmboy is available to chat with Members, comments are found below each post.
Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer. One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."
Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.
Genetic components are the DNA sequences that are 'inherited.' Some of these genes are stronger than others in their expression (e.g., eye color). Yet, some genes turn on or off due to external factors (environmental), and it is und...
Reminder: OpTrader is available to chat with Members, comments are found below each post.
This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).
We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options.
Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.
To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here
This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible. Feel free to contact me directly at firstname.lastname@example.org with any questions.
Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts. After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.) Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.
Note: The material presented in this commentary is provided for
informational purposes only and is based upon information that is
considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW)
nor its affiliates
warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Site owned and operated by PSW Investments, LLC. Contact us at: 403 Central Avenue, Hawthorne, NJ 07506. Phone: (201) 743-8009. Email: email@example.com.